

**NEXT GREEN WAVE HOLDINGS INC.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**For the Three and Six Months Ended June 30, 2020**

***Business of the Company***

Next Green Wave Holdings Inc. ("the Company"), is Canadian based, North American seed to sale cannabis company which provides products and services to the cannabis industry in California, United States through its wholly-owned subsidiaries, Next Green Wave, LLC ("NGW"), Crossgate Capital US Holdings Corp., NGW Holdings, LLC, and SDC Ventures, LLC.

This management discussion and analysis ("MD&A") of the financial condition and results of operations of the Company is for the three and six-month periods ended June 30, 2020.

This Management's Discussion and Analysis ("MD&A") is dated August 31, 2020, unless otherwise indicated and should be read in conjunction with the consolidated condensed interim financial statements of the Company or the three and six-months ended June 30, 2020 and the related notes. The Company's significant accounting policies are set out in Note 2 of the December 31, 2019 audited consolidated financial statements.

This MD&A was written to comply with the requirements of National Instrument 51-102 – Continuous Disclosure Obligations. Results are reported in US dollars, unless otherwise noted. In the opinion of management, all adjustments (which consist only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results presented as at June 30, 2020, are not necessarily indicative of the results that may be expected for any future period. These consolidated condensed interim financial statements are prepared in compliance with International Financial Reporting Standards for interim financial reporting.

For the purposes of preparing this MD&A, management, in conjunction with the Board of Directors, considers the materiality of information. Information is considered material if: (i) such information results in, or would reasonably be expected to result in, a significant change in the market price or value of the Company's common shares; or (ii) there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision; or (iii) if it would significantly alter the total mix of information available to investors. Management, in conjunction with the Board of Directors, evaluates materiality with reference to all relevant circumstances, including potential market sensitivity.

Further information about the Company and its operations can be obtained from the offices of the Company or from [www.sedar.com](http://www.sedar.com).

***Forward-Looking Statements***

This MD&A may contain "forward-looking statements" about the Company. In addition, the Company may make or approve certain statements in future filings with Canadian securities regulatory authorities, in press releases, or in oral or written presentations by representatives of the Company that are not statements of historical fact and may also constitute forward-looking statements. All statements, other than statements of historical fact, made by the Company that address activities, events or developments that the Company expects or anticipates will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as "may", "will", "would", "could", "should", "believes", "estimates", "projects", "potential", "expects", "plans", "intends", "anticipates", "targeted", "continues", "forecasts", "designed", "goal", or the negative of those words or other similar or comparable words and includes, among others, information regarding expectations of the effect of the Company; statements relating to the business and future activities of, and developments related to, the Company after the date of this MD&A; future business strategy, competitive strengths, goals, expansion and growth of the Company's business; operations and plans, including cultivation and licensing assets, and the grant of licenses or renewals; receipt of regulatory approvals in a timely manner or at all; the transfer and/or maintenance of licenses and third-party consents in a timely manner or at all; the expansion of existing cultivation and production facilities, including the completion of cultivation and production facilities that are under construction; any potential future legalization of adult-use and/or medical cannabis under U.S. federal law; expectations of market size and growth in the United States and the State of California; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future. These statements speak only as at the date they are made and are based on information currently available and on the then current expectations of the party making the statement and assumptions concerning future events, which are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from that which was expressed or implied by such forward-looking statements, including, but not limited to risks and uncertainties related to the following:

### Forward-Looking Statements (Continued)

- marijuana is illegal under U.S. federal law;
- marijuana is strictly regulated in those states which have legalized it for medical or recreational use;
- newly established legal regime;
- restricted access to banking;
- heightened scrutiny by Canadian and U.S. regulatory authorities;
- foreign investors in the Company and its directors, officers, and employees may be subject to entry bans into the United States;
- constraints on developing and marketing products;
- unfavorable tax treatment of cannabis businesses;
- risk of civil asset forfeiture;
- proceeds of crime statutes;
- limited intellectual property protection;
- lack of access to U.S. bankruptcy protections;
- potential FDA regulation;
- legality of contracts;
- limited operating history;
- actual results of operations may differ materially from the expectations of the Company's management;
- significant ongoing costs and obligations related to its investment in infrastructure, growth, regulatory compliance and operations;
- voting control;
- Next Green Wave Holdings Inc, being a holding company;
- the Company's products;
- unfavorable publicity or consumer perception;
- strategic alliances;
- risks inherent in an agricultural business;
- energy costs;
- reliance on key personnel;
- reliance on a single jurisdiction;
- unknown environmental risks;
- security risks;
- information technology risks;
- product recalls;
- results of future clinical research;
- competition;
- liquidity, financial resources and access to capital;
- licenses;
- future acquisitions or dispositions;
- insurance and uninsured risks;
- dependence on key inputs, suppliers and skilled labor;
- difficulty to forecast;
- management of growth;
- internal controls;
- failure to comply with anti-bribery laws;
- conflict of interest;
- litigation;
- product liability;
- general economic risks;
- Next Green Wave Holdings Inc, being a Canadian company and shareholder protections differ from shareholder protections in the United States and elsewhere;
- volatile market price for the Company's securities;
- the Company may not pay dividends;
- future sales or issuances of securities could decrease the value of securities, dilute investors' voting power and reduce earnings per share;

- the regulated nature of the Company's business may impede or discourage a takeover, which could reduce the market price of the Company's securities;
- there is no assurance the Company will continue to meet the listing standards of the Canadian Securities Exchange or the OTCQX
- Currency fluctuations; and
- other factors beyond the Company's control, as more particularly described under the heading "Risk Factors" in this MD&A.

Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information and statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such information and statements. Accordingly, readers should not place undue reliance on forward-looking information and statements as statements containing forward-looking information involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking information and statements contained herein are presented for the purposes of assisting readers in understanding the Company's expected financial and operating performance and the Company's plans and objectives and may not be appropriate for other purposes.

The cautionary statements contained or referred to in this section should be considered in connection with any subsequent written or oral forward-looking statements that the Company and/or persons acting on its behalf may issue. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required under securities legislation.

### ***Company Overview***

The Company was incorporated in the province of British Columbia on July 6, 2011. Its registered and records office is located at Suite 300 - 1055 West Hastings Street, Vancouver, B.C. V6E 2E9.

On October 10, 2018, the Company completed its Initial Public Offering ("IPO") and the Company's common shares are listed on the Canadian Securities Exchange ("CSE") under the trading symbol "NGW". In Q1 2019, the Company began trading on the OTCQX Best Market in the United States under the symbol "NXGWF".

The Company is a Canadian-based, North American seed to sale cannabis company which will provide products and services to the cannabis industry in the State of California, USA. The Company, through its wholly-owned subsidiary, Next Green Wave, LLC ("NGW"), is licensed by the State of California to produce, distribute and sell products throughout the State.

On April 18, 2019, the Company obtained the Certificate of Occupancy on its 35,000 square foot facility on one of its four properties zoned for cannabis production in City of Coalinga, CA ("Facility A"). Facility A enables the Company to cultivate medicinal and recreational cannabis, manufacture and distribute cannabis products in accordance with the requirements under the Medical and Adult Use Regulation and Safety Act (MAUCRSA).

### ***Key Developments***

On January 9, 2020, the Company appointed David Wilson and Rob Dzisiak (Chairman) to its Board of Directors. In addition, The Board updated the following governance committees:

- Audit Committee
  - David Wilson (Chairman)
  - Glen Harder
  - Michael Jennings
- Corporate Governance and Nominating Committee
  - Glen Harder (Chairman)
  - Paul Chow
  - Rob Dzisiak
- Compensation Committee
  - Rob Dzisiak (Chairman)
  - David Wilson
  - Michael Jennings

As of the date of this MD&A, the Company had the following products for sale, including:

- Loki the Dog ([www.lokinaturals.com](http://www.lokinaturals.com))
  - Full Spectrum 500mg & 1000mg CBD Tincture
  - Loki Love Bites
- Next Green Wave ([www.nextgreenwave.com](http://www.nextgreenwave.com))
  - Premium Bulk Flower
  - Premium Jarred Flower (3.5g)
  - Concentrate (Batter, Diamonds, Budder)

The Company wishes to emphasize the importance of the going concern assumption which can be referenced in Note 1 of the June 30, 2020 consolidated condensed interim financial statements and the Liquidity and Capital Resources section of this MD&A.

### Results of Operations

|  | For the three months ended |                       | For the six months ended |                       |
|--|----------------------------|-----------------------|--------------------------|-----------------------|
|  | June 30,<br>2020           | June 30,<br>2019      | June 30,<br>2020         | June 30,<br>2019      |
| <b>Revenue</b>   | <b>\$ 3,173,536</b>        | <b>\$ 58,023</b>      | <b>\$ 4,351,288</b>      | <b>\$ 58,023</b>      |
| <b>Cost of Sales</b>   | <b>(91,445)</b>            | <b>(17,711)</b>       | <b>(679,244)</b>         | <b>(17,711)</b>       |
| <b>Gross profit before fair value adjustments</b>                  | <b>3,082,091</b>           | <b>40,312</b>         | <b>3,672,044</b>         | <b>40,312</b>         |
| Fair value changes in biological assets included in inventory sold | (1,923,625)                | -                     | (2,759,517)              | -                     |
| Unrealized fair value adjustment on growth of biological assets    | (769,139)                  | (302,714)             | 444,225                  | (302,714)             |
| <b>Gross profit</b>  | <b>389,327</b>             | <b>(262,402)</b>      | <b>1,356,752</b>         | <b>(262,402)</b>      |
| <b>Operating Expenses</b>  |                            |                       |                          |                       |
| Bank charges   | 35,533                     | 2,448                 | 50,672                   | 3,997                 |
| Depreciation (Note 5)  | 219,443                    | 133,760               | 445,455                  | 133,760               |
| Directors fees (Note 17)   | 12,820                     | 5,613                 | 26,305                   | 13,564                |
| Foreign exchange loss  | 2,214                      | 20,308                | 8,962                    | 23,163                |
| General office   | 33,671                     | 130,591               | 92,641                   | 158,400               |
| Insurance  | 73,478                     | 90,997                | 141,822                  | 146,715               |
| Investor relations and communications                              | 88,057                     | 281,193               | 114,257                  | 1,021,645             |
| Royalty payments (Note 9)  | 12,109                     | 21,455                | 55,591                   | 21,455                |
| Professional fees  | 39,073                     | 112,287               | 55,657                   | 178,984               |
| Consulting services (Note 17)                                      | 30,521                     | 157,783               | 90,564                   | 355,074               |
| Regulatory and filing fees   | 7,429                      | 22,332                | 11,211                   | 24,423                |
| Salaries and management fees (Note 17)                             | 115,843                    | 99,712                | 439,258                  | 221,939               |
| Stock-based compensaton (Notes 12 & 17)                            | 74,628                     | 67,682                | 156,057                  | 794,745               |
| Travel, meals and entertainment                                    | 18,155                     | 52,477                | 63,478                   | 79,437                |
| <b>Total operating expenses</b>                                    | <b>762,974</b>             | <b>1,198,638</b>      | <b>1,751,930</b>         | <b>3,177,301</b>      |
| <b>Loss from operations</b>  | <b>(373,647)</b>           | <b>(1,461,040)</b>    | <b>(395,178)</b>         | <b>(3,439,703)</b>    |
| <b>Other Expenses (Income)</b>                                     |                            |                       |                          |                       |
| Transaction costs  | 71,042                     | 750,000               | 71,042                   | 750,000               |
| Unrealized gain on investments (Note 6)                            | (1,175,334)                | -                     | (960,184)                | -                     |
| Reversal of impairment of assets (Note 5)                          | (2,447,948)                | -                     | (2,447,948)              | -                     |
| Interest and accretion expense (Notes 8, 10 & 14)                  | 285,774                    | 60,102                | 572,479                  | 60,102                |
| Interest income  | (966)                      | (28)                  | (966)                    | (6,877)               |
| <b>Net income (loss) for the period</b>                            | <b>2,893,785</b>           | <b>(2,271,114)</b>    | <b>2,370,399</b>         | <b>(4,242,928)</b>    |
| <b>Other comprehensive income (loss)</b>                           |                            |                       |                          |                       |
| Cumulative translation income (loss)                               | 1,928                      | 13,691                | (12,014)                 | 26,957                |
| <b>Total comprehensive income (loss) for the period</b>            | <b>\$ 2,895,713</b>        | <b>\$ (2,257,423)</b> | <b>\$ 2,358,385</b>      | <b>\$ (4,215,971)</b> |

For the three and six months ended June 30, 2020 and 2019

*Revenue*

The Company earned revenue of \$3,173,536 and \$4,351,288 for the three and six-month periods ended June 30, 2020 and as compared with \$58,023 for both the three and six-month periods ended June 30, 2019. The revenue is comprised of CBD sales, bulk flower sales and packaged flower sales.

*Cost of Goods Sold*

Cost of goods sold was \$91,445 and \$679,244 for the three and six-month periods ended June 30, 2020 as compared with the cost of goods sold loss of \$17,711 for both the three and six-month periods ended June 30, 2019. Cost of goods sold includes production costs expensed and the cost of inventory sold. Direct and indirect production costs include direct labor, processing, testing, packaging, quality assurance, inventory and shipping.

*Cost of Goods Sold – Fair Value Adjustments*

Cost of goods sold in fair value adjustment on growth of biological assets was \$769,139 and gain of \$444,225 for the three and six-month periods ended June 30, 2020 as compared with \$302,714 for both the three and six-month periods ended June 30, 2019. This amount represents the effect of the non-cash fair value adjustments of biological assets produced in the period, excluding capitalized production costs. This balance is netted against the non-cash fair value adjustments capitalized to inventory being recognized in the statement of operations as the corresponding inventory is sold.

*Other Income and Expenses*

\$1,175,334 and \$960,184 of unrealized gain on change in fair value of investments for the three and six-month periods ended June 30, 2020 as compared with \$nil for both the three and six-month periods ended June 30, 2019, related to ownership of common shares of Cannabis Growth Opportunity Corporation ("CGOC").

\$2,447,948 of reversal on impairment of assets for both the three and six-month periods ended June 30, 2020 as compared with \$nil for both the three and six-month periods ended June 30, 2019, related to a reversal of an impairment originally recorded in 2019. It was recognized immediately in the consolidated statements of operations for the property, plant and equipment.

\$966 in interest income for both the three and six-month periods ended June 30, 2020 as compared with \$28 and \$6,877 for the three and six-month periods ended June 30, 2019. This income relates to interest earned on term deposits.

\$71,042 in transaction costs for both the three and six-month periods ended June 30, 2020. This amount represents the costs associated with the disposition of SDC Ventures, LLC assets.

\$2,214 and \$8,962 of foreign exchange and cumulative translation loss for the three and six-month periods ended June 30, 2020, related to the Company's cash balances held in CAD\$ and the convertible debentures;

\$285,774 and \$572,479 in interest expense for the three and six-month periods ended June 30, 2020, related to the convertible debentures and asset backed loan;

*Operating Expenses*

\$74,628 and \$156,057 of share-based compensation for the three and six-month periods ended June 30, 2020.

\$12,109 and \$55,591 in royalty payments, related to the brand licensing agreements, for the three and six-month periods ended June 30, 2020. The decrease in royalty payment is due to a shift in focus in developing internal brands.

\$82,414 and \$172,526 in professional, consulting and director fees for the three and six-month periods ended June 30, 2020. These expenses include compliance, accounting and legal fees;

\$109,011 and \$192,494 in insurance and bank fees for the three and six-month periods ended June 30, 2020. These expenses include day-day cannabis banking services, general liability, product liability and D&O insurance.

\$219,443 and \$445,455 depreciation for the three and six-month periods ended June 30, 2020.

\$41,100 and \$103,852 in general office and regulatory and filing fees for the three and six-month periods ended June 30, 2020.

\$88,057 and \$114,257 in Investor relations and communications for the three and six-month periods ended June 30, 2020. These amounts relate to costs incurred by to promote the Company, including investor relations, marketing and public relations;

\$115,843 and \$439,258 in salary and management fees for the three and six-month periods ended June 30, 2020. These amounts include the management team both in Canada and California.

\$18,155 and \$63,478 in travel costs for the three and six-month periods ended June 30, 2020. These expenses include operational support, investor relations, project management and financing activities. The decrease in travel costs is primarily related to the COVID19 pandemic limiting travel for employees.

2020 Operating Expenses have increased when compared to 2019 due to operations not commencing until Q2 2019. The main exception to this is investor relations expenses, which has decreased significantly in 2020 as a result of a shift in focus to operational expenditures.

### **Selected Quarterly Information**

The following table sets out selected quarterly information for the last 8 completed fiscal quarters of the Company:

|                                  | Q2<br>2020   | Q1<br>2020   | Q4<br>2019   | Q3<br>2019  | Q2<br>2019  | Q1<br>2019  | Q4<br>2018  | Q3<br>2018  |
|----------------------------------|--------------|--------------|--------------|-------------|-------------|-------------|-------------|-------------|
| Revenue                          | \$ 3,173,536 | \$ 1,177,752 | \$ 144,036   | \$ 83,894   | \$ 58,023   | \$ -        | \$ -        | \$ -        |
| Operating expenses               | (762,974)    | (988,956)    | (1,485,203)  | (1,185,367) | (1,198,638) | (1,978,663) | (1,679,326) | (1,066,100) |
| Comprehensive income/(loss)      | 2,895,713    | (537,328)    | (11,195,442) | (801,546)   | (2,257,423) | (1,958,548) | (1,812,640) | (1,042,411) |
| Basic and diluted loss per share | \$ (0.02)    | \$ (0.00)    | \$ (0.08)    | \$ (0.06)   | \$ (0.02)   | \$ (0.02)   | \$ (0.01)   | \$ (0.01)   |
| Total assets                     | 18,522,088   | 15,551,610   | 15,847,681   | 28,409,600  | 28,397,088  | 14,343,381  | 15,110,765  | 18,381,578  |
| Current Liabilities              | 2,107,062    | 1,113,214    | 1,105,826    | 243,150     | 450,057     | 95,406      | 292,092     | 136,229     |
| Total Liabilities                | 5,042,394    | 4,823,705    | 4,680,940    | 1,150,677   | 840,504     | 95,406      | 292,092     | 136,229     |
| Shareholders' equity             | 13,479,694   | 10,727,905   | 11,166,741   | 27,258,923  | 27,556,584  | 14,247,975  | 14,818,673  | 18,245,349  |
| Dividends declared               | \$ -         | \$ -         | \$ -         | \$ -        | \$ -        | \$ -        | \$ -        | \$ -        |

### **Liquidity and Capital Resources**

The Company's objective when managing its liquidity and capital resources are to generate sufficient cash to fund the Company's development, operating and organic growth opportunities.

As at June 30, 2020, the Company's cash position, including short-term investments, was \$1,477,519 compared to \$1,241,747 at December 31, 2019. Working capital at June 30, 2020 was \$2,760,720 compared to \$3,051,935 at December 31, 2019.

From January 1, 2020, to the date of this MD&A, the Company completed the following equity transactions:

#### **Stock Options**

On January 9, 2020, the Company granted a total of 1,700,000 to Directors with an exercise price of CDN\$0.15 per share:

- 850,000 options, which vest 25% at the end of every 3 months for a period of 12 months, with a term of five years.
- 850,000 options, which vest 25% at the end of every 6 months for a period of 24 months, with a term of five years.

On February 27, 2020, the Company granted 750,000 options to employees and with an exercise price of CDN\$0.15 per share which vest 25% at the end of every 6 months for a period of 24 months, with a term of five years.

On March 31, 2020, 250,000 options were forfeited, and, subsequent to June 30, 2020, an additional 100,000 options were forfeited.

On July 7, 2020, the Company granted 3,000,000 stock options under its Stock Option Plan, exercisable at a price of CDN\$0.15 per share for two directors. The stock options are five-year options which will vest 25% every six months for a period of two years.

### **Share Capital**

On May 31, 2020, the Company executed an Asset Purchase Agreement with two former employees (the "Employees") of the Company and former shareholders of SDC, where the Company transferred to the Employees the following Company assets for the return to treasury of 5,163,406 common shares previously issued by the Company to the Employees:

- SD Cannabis brand name
- Inventory
- One brand license agreement.
- A lease agreement

On August 13, 2020, CDN\$750,000 of the Debentures were converted at a price of CDN\$0.15 and resulted in the issuance of 5,000,000 common shares of the Company.

### **Off-Balance Sheet Arrangements and Contractual Obligations**

The Company does not have any off-balance sheet arrangements or contractual obligations.

### **Related Party Transactions**

A summary of compensation for directors, officers and key management personnel is as follows:

|                                  | Three Month Period Ended |                   | Six Month Period Ended |                   |
|----------------------------------|--------------------------|-------------------|------------------------|-------------------|
|                                  | June 30,<br>2020         | June 30,<br>2019  | June 30,<br>2020       | June 30,<br>2019  |
| Management fee (1)               | \$ 59,948                | \$ 30,000         | \$ 120,269             | \$ 60,000         |
| Director and consulting fees (2) | 29,418                   | 48,975            | 63,032                 | 99,735            |
| Stock based compensation (3)     | 56,703                   | 120,543           | 111,172                | 296,293           |
| <b>Total</b>                     | <b>\$ 146,069</b>        | <b>\$ 199,518</b> | <b>\$ 294,473</b>      | <b>\$ 456,028</b> |

- 1) The CEO and CFO's Management Fee is included in Management fees on Consolidated Condensed Interim Statements of Operations and Comprehensive Income (Loss) for each of the periods.
- 2) Director and Consulting fees paid to the directors and officers of the Company to provide accounting, management consulting and director services. These fees are included on the Consolidated Condensed Interim Statements of Operations and Comprehensive Income (Loss) for each of the periods.
- 3) Amounts recognized for related party stock-based compensation are included in Share-based payments on the Consolidated Condensed Interim Statements of Operations and Comprehensive Income (Loss) for each of the periods.

### **Outlook**

The Company continues to retrofit Facility C ("Facility C") to accommodate the Company's commercial extraction, manufacturing, infusion and distribution operations for cannabis oils, cannabis extracts, cannabinoid infused products, and facility research and development cannabis projects. Commercial operations for Facility C are expected to commence by Q4 2020.

In Q4 2020, the Company will evaluate plans to construct:

- a 50,000 square foot facility ("Facility B"), which is immediately adjacent to Facility A to accommodate the expansion of the nursery, flower manufacturing and distribution operations.
- Develop a light deprivation 250,000 square foot greenhouse on Lot D ("Facility D").

The Company owns all the land related to all its Facility A, B, C & D, and anticipates that it will require additional funding to fully finance the Facility B & D projects.

The recent outbreak of the coronavirus, also known as "COVID-19", has spread across the globe and is impacting worldwide economic activity. Conditions surrounding the coronavirus continue to rapidly evolve and government authorities have implemented emergency measures to mitigate the spread of the virus. As at the financial statement approval date, the outbreak and the related mitigation measures have had the following impacts on the Company's operations, among others:

- staff layoffs
- decline in the value of investments

The extent to which these events may impact the Company's business activities will depend on future developments, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine the ultimate financial impacts at this time.

In Q4 2020, the Company expects to:

- Continue its cannabis cultivation operations
- Launch a series of NGW products and brands
- Commence extraction operations
- Expand online sales for direct to consumer CBD products
- Expand sales to dispensaries
- Commence nursery sales
- Continue to develop commercial sales channels to sell packaged products and bulk flower

#### **Legal Proceedings**

The Company is not aware of any legal proceedings or claims where there is at least a reasonable possibility that a material loss may be incurred.

#### **Critical Accounting Estimates**

The preparation of the Financial Statements in conformity with IFRS requires management to make judgments, estimates, and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting period, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the inputs used in the Black-Scholes Option Pricing Model to measure stock-based compensation and warrant valuation, determination of the useful life of equipment, fair value estimates for private investments, estimated yields and fair value less costs to sell related to biological assets and the provision for income taxes.

#### **Outstanding Share Data**

The Company's authorized share capital consists of an unlimited number of Common Shares without par value. As at the date of this MD&A:

|                               |                    |
|-------------------------------|--------------------|
| Common Shares*                | 164,506,783        |
| Incentive Stock Options       | 8,630,000          |
| Convertible Debentures        | 5,000,000          |
| Finders Units – Common Shares | 541,265            |
| Finders Units – Warrants      | 541,265            |
| Warrants                      | 15,232,357         |
| <i>Fully Diluted Shares</i>   | <i>194,451,670</i> |

\* 32,637,250 common shares are held in escrow as of the date of this MD&A.

## Risks and Uncertainties

### Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The carrying amounts of cash and accounts receivable on the consolidated condensed interim financial position represent the Company's maximum credit exposure at June 30, 2020. The Company reduces its credit risk on cash by placing cash with institutions of high credit worthiness and by monitoring customers creditworthiness on an ongoing basis. All accounts receivable as at June 30, 2020 are less than 90 days old and no allowance for doubtful accounts have been recognized.

### Liquidity risk

The Company ensures there is sufficient capital to meet its short-term business requirements, after taking into account the Company's holdings of cash and cash equivalents and short-term investments. The Company's cash equivalents, and short-term investments are held with a Canadian financial institution and is available on demand. The Company will continue to rely on additional financings to further its operations and to meet its capital requirements. Liquidity risk is assessed as high.

### Market risk

The Company is exposed to foreign exchange risk as it conducts business in both the United States and Canada. Management monitors its foreign currency balances and the Company does not engage in any hedging activities to reduce its foreign currency risk.

At June 30, 2020, the Company was exposed to currency risk through the following monetary assets and liabilities in CDN Dollars.

|  |    |             |
|--|----|-------------|
| Cash                                     | \$ | 25,950      |
| Interest and other receivable            |    | 12,464      |
| Convertible Debentures                   |    | (1,291,841) |
| Accounts payable and accrued liabilities |    | (48,548)    |
|  | \$ | (1,301,975) |

Based on the net exposure and assuming all other variables remain constant, a 10% change in the appreciation or depreciation of the Canadian dollar relative to the US dollar would result in a change of approximately CDN\$130,198 to operations for the year.

The contractual interest of the convertibles debentures is fixed and the secured loan is variable at a rate of 10.5% per annum; plus (ii) the greater of (a) 2.5% and (b) LIBOR rate; plus any default rate. Management monitors the variable interest rate and the Company does not engage in any hedging activities to reduce its interest rate risk.

### **Risk Factors**

The following information is a summary only and the risks and uncertainties below are not the only ones related to our Company but are related to the industry at large. There are additional risks and uncertainties that our Company does not presently know of or that our Company currently considers immaterial which may impair our Company's business operations. If any of the following risks occur, our business may be harmed, and its financial condition and results of operations may suffer significantly. In such circumstances, the share price of our common shares could decline, and investors may lose all or part of their investment.

### **Access to Capital**

As of June 30, 2020, the Company had cash of \$1,477,519 and net income of \$2,370,399 for the period six month period then ended. As such, the Company may require additional financing in the near future to develop and to expand its business operations. The Company and may not be able to obtain financing when required. Obtaining additional financing would be subject to a number of factors, including our Company's ability to initially attract investments prior to substantial revenue generation, and thereafter the Company's ability to grow its operations. If the Company is unable to continue as a going concern, investors will likely lose all their investments in the Company.

***Marijuana is illegal under U.S. federal law***

The cultivation, manufacture, distribution, and possession of marijuana is illegal under U.S. federal law. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and, in case of conflict between federal and state law, the federal law must be applied. Accordingly, federal law applies even in those states in which the use of marijuana has been legalized. Enforcement of federal law regarding marijuana would harm the Company's business, prospects, results of operation, and financial condition.

Under the Controlled Substances Act, 21 U.S.C. (the "CSA"), § 801 et seq., it is a felony to manufacture, distribute, dispense or possess with intent to manufacture, distribute or dispense a controlled substance, including marijuana (a Schedule I drug under the CSA); to use a communication facility, which includes the mail, telephone, wire, radio, and all other means of communication, to cause or facilitate a violation of the CSA; and to place an advertisement knowing that the advertisement is intended to offer to sell or buy marijuana, or to use the internet to advertise the sale of marijuana. It is also a federal misdemeanor to knowingly or intentionally possess marijuana and a felony to attempt or conspire to violate the CSA. The CSA does not apply to conduct that takes place entirely outside the United States if the conduct involves cannabis that never reaches, and is never intended to reach, the United States.

Since the possession and use of cannabis and any related drug paraphernalia is illegal under U.S. federal law, the Company may be deemed to be aiding and abetting illegal activities. Its subsidiaries plan to manufacture and/or distribute medical and adult-use cannabis. As a result, U.S. law enforcement authorities, in their attempt to regulate the illegal use of cannabis and any related drug paraphernalia, may seek to bring an action or actions against the Company or its subsidiaries, including, but not limited to, a claim regarding the possession, use and sale of cannabis, and/or aiding and abetting another's criminal activities. The U.S. federal aiding and abetting statute provides that anyone who "commits an offense or aids, abets, counsels, commands, induces or procures its commission, is punishable as a principal." As a result, the U.S. Department of Justice, under the current administration, could allege that the Company has "aided and abetted" violations of federal law by providing financing and services to its subsidiaries. Under these circumstances, the federal prosecutor could seek to seize the assets of the Company, and to recover the "illicit profits" previously distributed to shareholders resulting from any of the foregoing. In these circumstances, the Company's operations would cease, shareholders may lose their entire investment and directors, officers and/or shareholders may be left to defend any criminal charges against them at their own expense and, if convicted, be sent to federal prison. Such an action would result in a material adverse effect on the Company.

Violations of federal law could result in significant fines, penalties, administrative sanctions, criminal prosecution, including arrest, pre-trial incarceration, and sentences including monetary fines or incarceration, disgorgement of profits, cessation of business activities or divestiture, and forfeiture of real and personal property. The federal government can seek, (i) civil forfeiture of property involved in or traceable to certain crimes, including money laundering and violations of the CSA; and (ii) prosecution of the Company's employees, directors, officers, managers and investors for criminal violations of the CSA, federal anti-money laundering laws, or the Travel Act. Even when the government does not bring criminal charges, it may use the threat of an investigation or charges to incentivize civil settlements. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its holding (directly or indirectly) of cannabis licenses in the United States, the listing of its securities on various stock exchanges, its financial position, operating results, profitability or liquidity or the market price of its publicly traded Common Shares. It is difficult to estimate the time or resources needed to respond to a government investigation or prosecution of such matters without knowing the nature and extent of any information requested by the applicable authorities involved. Such time or resources could be substantial.

***Marijuana is strictly regulated in those states which have legalized it for medical or recreational use***

U.S. states and territories that have medical and/or adult-use markets impose substantial regulatory and licensing burdens on marijuana businesses. The legal and regulatory framework applicable to cannabis businesses is different in every state and territory. Obtaining a license or permit to grow, distribute, or dispense marijuana can be a difficult, costly, and lengthy process. Violations of a state's legal and regulatory framework can result in revocation of licenses, civil penalties, and other punishments. No assurance can be given that the Company will receive the requisite licenses, permits, or cards to operate its businesses.

Local laws and ordinances could restrict the Company's business activity. Local governments may have the ability to limit or ban cannabis businesses from operating within their jurisdiction, or impose requirements in addition to those imposed by state law. Land use, zoning, local ordinances, and similar laws could be adopted or changed, which may have a material adverse effect on the Company's business.

The Company currently operates only in the State of California, but may consider opportunities in other jurisdictions as deemed appropriate by management. The Company is aware that multiple states are considering special taxes or fees on businesses in the marijuana industry. Other states may be in the process of reviewing such additional fees and taxation, or may impose them in the future. This could have a material adverse effect upon the Company's business, results of operations, financial condition, or prospects.

***Newly established legal regime***

The Company's business activities will rely on newly established and/or developing laws and regulations in the state in which it operates. These laws and regulations are rapidly evolving and subject to change with minimal notice. Regulatory changes may adversely affect the Company's profitability or cause it to cease operations entirely. The cannabis industry may come under the scrutiny or further scrutiny by the FDA, Securities and Exchange Commission, the Department of Justice, the Financial Industry Regulatory Advisory or other federal or applicable state or nongovernmental regulatory authorities or self-regulatory organizations that supervise or regulate the production, distribution, sale or use of cannabis for medical or nonmedical purposes in the United States. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding the industry may adversely affect the business and operations of the Company, including without limitation, the costs to remain compliant with applicable laws and the impairment of its business or the ability to raise additional capital.

***Restricted access to banking***

The Company may have limited or no access to banking or other financial services in the United States. Federal anti-money laundering statutes and regulations discourage financial institutions from working with marijuana businesses, regardless of whether marijuana is legal in the state in which the financial institution or its customers are located. The inability or limitation in the Company's ability to open or maintain bank accounts, obtain other banking services, or accept credit card and debit card payments may make it difficult for the Company to operate and conduct its business as planned or to operate efficiently.

Federally chartered financial institutions are subject to federal regulation, including oversight by the Financial Crimes Enforcement Network ("FinCEN") bureau of the U.S. Treasury Department. Because marijuana is illegal under federal law, financial institutions may subject themselves to federal civil or criminal liability for banking the proceeds of marijuana businesses, and there are relatively few financial institutions who provide banking services to marijuana businesses.

The FinCEN Guidance does not provide any safe harbors or legal defenses from examination or regulatory or criminal enforcement actions by the U.S. Department of Justice, FinCEN or other federal regulators. Thus, most banks and other financial institutions in the United States do not appear to be comfortable providing banking services to cannabis-related businesses, or relying on this guidance, which can be amended or revoked at any time by the Trump Administration.

Financial institutions which do provide financial services to marijuana businesses may charge increased fees to or impose additional requirements on marijuana businesses. Some financial institutions refuse to process debit or credit card payments to marijuana businesses. Financial institutions which process such transactions may also charge fees higher than those imposed on other businesses. The Company may experience increased costs, or decreased profits, as a result of its inability to accept debit or credit card payments, or as a result of increased fees it pays to the financial institutions processing such transactions.

Further, because the manufacture, distribution, and dispensation of cannabis remains illegal under the CSA, banks and other financial institutions providing services to cannabis-related businesses risk violation of federal anti-money laundering statutes (18 U.S.C. §§ 1956 and 1957), the unlicensed money-remitter statute (18 U.S.C. § 1960) and the U.S. Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), as amended and the rules and regulations thereunder, the Criminal Code (Canada) and other related or similar rules, regulations or guidelines, issued, administered or enforced by governmental authorities in the United States and Canada.

Participating in transactions involving proceeds derived from cannabis may constitute criminal money laundering. It is a federal crime to engage in certain transactions involving the proceeds of "Specified Unlawful Activities" ("SUA") when those transactions are designed to promote an underlying SUA, or conceal the source of the funds. Violations of the CSA and violations of a foreign state's laws are both SUA. It is a federal crime in the United States to engage in an international transaction into or out of the United States if the transaction is intended to promote an SUA, irrespective of the source of the funds. It is a federal crime to engage in a transaction in property worth greater \$10,000 knowing that the property is derived from a SUA. In the event that any of the Company's investments, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such investments in the United States were found to be in violation of anti-money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under one or more of the statutes of the United States or any other applicable legislation. This could restrict or otherwise jeopardize the ability of the Company to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada and other foreign jurisdictions from the United States.

***Heightened scrutiny by Canadian and U.S. regulatory authorities***

The Company's existing operations in the United States, and any future operations or investments, may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada and the United States. As a result, the Company may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Company's ability to operate or invest in the United States or any other jurisdiction, in addition to those described herein.

While there is no ban on CDS Clearing and Depository Services Inc. ("CDS") clearing of securities of issuers with cannabis-related activities in the United States, there can be no guarantee that this approach to regulation will continue in the future. If such a ban were to be implemented, it would have a material adverse effect on the ability of holders of Common Shares to make and settle trades. In particular, Common Shares would become highly illiquid until an alternative was implemented, investors would have no ability to affect a trade of the Common Shares through the facilities of the applicable stock exchange.

***Foreign investors in the Company and the Company's directors, officers, and employees may be subject to entry bans into the United States***

It is a federal crime to engage in interstate or foreign travel or commerce with the intent to distribute the proceeds of or promote a SUA. News media have reported that United States immigration authorities have increased scrutiny of people who are crossing the United States-Canada border with respect to persons involved in cannabis businesses in the United States.

Those employed at or investing in legal and licensed Canadian cannabis companies could face detention, denial of entry or lifetime bans from the United States for their business associations with U.S. cannabis businesses. Entry happens at the sole discretion of CBP officers on duty, and these officers have wide latitude to ask questions to determine the admissibility of a non-US citizen or foreign national. The government of Canada has started warning travelers on its website that previous use of cannabis, or any substance prohibited by U.S. federal laws, could mean denial of entry to the United States. Business or financial involvement in the legal cannabis industry in Canada or in the United States could also be reason enough for U.S. border guards to deny entry. On September 21, 2018, CBP released a statement outlining its current position with respect to enforcement of the laws of the United States. It stated that Canada's legalization of cannabis will not change CBP enforcement of United States laws regarding controlled substances and because cannabis continues to be a controlled substance under United States law, working in or facilitating the proliferation of the legal marijuana industry in the United States remains prohibited.

States where it is deemed legal or Canada may affect admissibility to the United States. As a result, CBP has affirmed that, employees, directors, officers, managers and investors of companies involved in business activities related to cannabis in the United States or Canada (such as the Company), who are not U.S. citizens face the risk of being barred from entry into the United States for life. On October 9, 2018, CBP released an additional statement regarding the admissibility of Canadian citizens working in the legal cannabis industry. CBP stated that a Canadian citizen working in or facilitating the proliferation of the legal cannabis industry in Canada coming into the United States for reasons unrelated to the cannabis industry will generally be admissible to the United States; however, if such person is found to be coming into the United States for reasons related to the cannabis industry, such person may be deemed inadmissible. Accordingly, the Company's directors, officers or employees traveling to the United States for the benefit of the Company may encounter enhanced scrutiny by United States immigration authorities that may result in the employee not being permitted to enter the United States for a specified period of time. If this happens to the Company's directors, officers or employees, then this may reduce our ability to manage our business effectively in the United States.

### ***Constraints on developing and marketing products***

The development of the Company's business and operating results may be hindered by applicable restrictions on development, sales and marketing activities imposed by government regulatory bodies. The legal and regulatory environment in the United States limits the Company's ability to compete for market share in a manner similar to other industries. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by government authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect on the Company's business, results of operation and financial condition.

If the Company is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, the Company's sales and operating results could be adversely affected.

### ***Unfavorable tax treatment of cannabis businesses***

Under Section 280E ("Section 280E") of the United States Internal Revenue Code of 1986 as amended, "no deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any state in which such trade or business is conducted.". This provision has been applied by the U.S. Internal Revenue Service to cannabis operations, prohibiting them from deducting expenses directly associated with the sale of cannabis. Although the U.S. Internal Revenue Service issued a clarification allowing the deduction of certain expenses that can be categorized as cost of goods sold, the scope of such items is interpreted very narrowly and include the cost of seeds, plants, and labor related to cultivation, while the bulk of operating costs and general administrative costs are not permitted to be deducted. Section 280E therefore has a significant impact on the retail side of cannabis, but a lesser impact on cultivation, processing, production and packaging operations. A result of Section 280E is that an otherwise profitable business may, in fact, operate at a loss, after taking into account its U.S. income tax expenses.

### ***Risk of civil asset forfeiture***

United States federal law enforcement officials are empowered to seize property they allege has been involved in certain criminal activity. Because marijuana remains illegal under U.S. federal law, property owned by marijuana businesses could be subject to seizure and subsequent civil asset forfeiture by law enforcement, whether or not the owner is charged with a crime. Property can be seized and forfeited through criminal, civil, and administrative proceedings. Property owners seeking the return of their property must establish that the property was not involved in criminal activity, which can be a substantial burden.

### ***Proceeds of crime statutes***

The Company is subject to a variety of laws and regulations domestically and in the United States relating to money laundering, financial recordkeeping, and proceeds of crime, including the BSA, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), as amended and the rules and regulations thereunder, the Criminal Code (Canada) and any related or similar rules, regulations or guidelines, issued, administered or enforced by governmental authorities in the United States and Canada.

In the event that any of the Company's license agreements in the United States are found to be illegal, proceeds of those licensing transactions may be viewed as proceeds of crime under one or more of the statutes noted above or any other applicable legislation. This could be materially adverse to the Company and, among other things, could restrict or otherwise jeopardize the ability of the Company to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada.

### ***Limited intellectual property protection***

The Company's ability to compete may depend on the superiority, uniqueness and value of any intellectual property and technology that it may develop. To the extent the Company is able, to protect its proprietary rights, the Company intends to rely on a combination of patent, trademark, copyright and trade secret laws, confidentiality agreements with its employees and third parties, and protective contractual provisions. Despite these efforts, there may be occurrences or impediments that may reduce the value of any of the Company's intellectual property, including the following:

The Company will not be able to register any United States federal trademarks for its cannabis products. Because producing, manufacturing, processing, possessing, distributing, selling, and using cannabis is a crime under the CSA, the United States Patent and Trademark Office will not permit the registration of any trademark that identifies cannabis products. As a result, the Company likely will be unable to protect its cannabis product trademarks beyond the geographic areas in which it conducts business. The use of its trademarks outside the states in which it operates by one or more other persons could have a material adverse effect on the value of such trademarks.

Patents in the cannabis industry involve complex legal and scientific questions and patent protection may not be available for some or any products and as a result the Company may have to rely on goodwill associated with its trademarks, trade names and proprietary cannabis strains.

The Company may be exposed to infringement or misappropriation claims by third parties, which, if determined adversely to the Company, could subject the Company to significant liabilities and other costs.

The Company's success may likely depend on its ability to use and develop new extraction technologies, recipes, know-how and new strains of cannabis without infringing the intellectual property rights of third parties. The Company cannot assure that third parties will not assert intellectual property claims against it. The Company is subject to additional risks if entities licensing to it intellectual property do not have adequate rights in any such licensed materials. If third parties assert copyright or patent infringement or violation of other intellectual property rights against the Company, it will be required to defend itself in litigation or administrative proceedings, which can be both costly and time consuming and may significantly divert the efforts and resources of management personnel.

An adverse determination in any such litigation or proceedings to which the Company may become a party could subject it to significant liability to third parties, require it to seek licenses from third parties, to pay ongoing royalties or subject the Company to injunctions prohibiting the development and operation of its applications.

### ***Lack of access to U.S. bankruptcy protections***

Because the use of cannabis is illegal under federal law, many courts have denied cannabis businesses bankruptcy protections, thus making it very difficult for lenders to recoup their investments in the cannabis industry in the event of a bankruptcy. If the Company were to experience a bankruptcy, there is no guarantee that U.S. federal bankruptcy protections would be available to the Company, which would have a material adverse effect.

### ***Potential FDA regulation***

Should the federal government legalize cannabis, it is possible that the FDA, would seek to regulate it under the Food, Drug and Cosmetics Act of 1938. Additionally, the FDA may issue rules and regulations including good manufacturing practices, related to the growth, cultivation, harvesting and processing of medical cannabis. Clinical trials may be needed to verify efficacy and safety. It is also possible that the FDA would require that facilities where medical-use cannabis is grown register with the FDA and comply with certain federally prescribed regulations. In the event that some or all of these regulations are imposed, the impact they would have on the cannabis industry is unknown, including what costs, requirements and possible prohibitions may be enforced. If the Company is unable to comply with the regulations or registration as prescribed by the FDA it may have an adverse effect on the Company's business, operating results and financial condition.

### ***Legality of contracts***

The Company's contracts involve cannabis and other activities that are not legal under U.S. federal law and in some jurisdictions. The Company may face difficulties in enforcing its contracts in U.S. federal and certain state courts. The inability to enforce any of the Company's contracts could have a material adverse effect on its business, operating results, financial condition, or prospects.

## **Risks Related to the Company**

### ***Limited operating history***

As the Company just begun to generate revenue and it has recently completed its first commercial cannabis crop at Facility A, it is extremely difficult to make accurate predictions and forecasts of its finances. This is compounded by the fact that the Company intends to operate in the cannabis industry, which is rapidly transforming. There is no guarantee that the Company's products will be attractive to potential consumers or that the revenues generated from such products will meet the Company's projections. In addition, the Company is subject to all of the business risks and uncertainties associated with any early-stage enterprise, including under-capitalization, cash shortages, limitations with respect to personnel, financial and other resources, and lack of revenues. The Company has been incurring operating losses. The Company may not be able to achieve or maintain profitability and may continue to incur significant losses in the future. Furthermore, the Company expects to continue to increase operating expenses as it implements initiatives to grow its business. There is no assurance that the Company will be successful in achieving a return on shareholders' investments and the likelihood of success must be considered in light of the early stage of the Company's operations.

### ***Actual results of operations may differ materially from the expectations of the Company's management***

The Company's actual financial position and results of operations may differ materially from management's expectations. As a result, the Company's revenue, net income and cash flow may differ materially from the Company's projected revenue, net income and cash flow. The process for estimating the Company's revenue, net income and cash flow requires the use of judgment in determining the appropriate assumptions and estimates. These estimates and assumptions may be revised as additional information becomes available and as additional analyses are performed. In addition, the assumptions used in planning may not prove to be accurate, and other factors may affect the Company's financial condition or results of operations.

### ***Significant ongoing costs and obligations related to its investment in infrastructure, growth, regulatory compliance and operations***

The Company expects to incur significant ongoing costs and obligations related to its completion of Facility C and its ongoing operations, and other infrastructure, as well as for growth and for regulatory compliance. These costs, particularly if they exceed budget amounts, could have a material adverse impact on the Company's results of operations, financial condition and cash flows. In addition, future changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company. The Company's efforts to grow its business may be costlier than the Company expects, and the Company may not be able to increase its revenue enough to offset its higher operating expenses. The Company may incur significant losses in the future for a number of reasons, including unforeseen expenses, the delay of the completion of Facility C, the delay or reduction in commercial cannabis crops, unforeseen reductions in the price of the Company's products due to changes in supply and demand, and other unknown events. If the Company is unable to achieve and sustain profitability, the market price of the Common Shares may significantly decrease.

### ***The Company is a holding company***

The Company is a holding company and essentially all of its assets are the capital stock of its subsidiaries. As a result, investors in the Company are subject to the risks attributable to its subsidiaries. As a holding company, the Company conducts substantially all of its business through its subsidiaries, which generate or are expected to generate substantially all of its revenues. Consequently, the Company's cash flows and ability to complete current or desirable future enhancement opportunities are dependent on the earnings of its subsidiaries and the distribution of those earnings to the Company. The ability of these entities to pay dividends and other distributions will depend on their operating results and will be subject to applicable laws and regulations which require that solvency and capital standards be maintained by such companies and contractual restrictions contained in the instruments governing their debt. In the event of a bankruptcy, liquidation or reorganization of any of the Company's material subsidiaries, holders of indebtedness and trade creditors may be entitled to payment of their claims from the assets of those subsidiaries before the Company.

### ***The Company's products***

As a relatively new industry, there are not many established players in the recreational cannabis industry whose business model the Company can follow or build on the success of. Similarly, there is little information about comparable companies available for potential investors to review in making a decision about whether to invest in the Company.

Shareholders and investors should further consider, among other factors, the Company's prospects for success in light of the risks and uncertainties encountered by companies that, like the Company, are in their early stages. For example, unanticipated expenses and problems or technical difficulties may occur and they may result in material delays in the operation of the Company's business. The Company may not successfully address these risks and uncertainties or successfully implement its operating strategies. If the Company fails to do so, it could materially harm the Company's business to the point of having to cease operations and could impair the value of the Common Shares to the point investors may lose their entire investment.

The Company expects to commit significant resources and capital to develop and market existing products and new products and services. These products are relatively untested, and the Company cannot assure shareholders and investors that it will achieve market acceptance for these products, or other new products and services that the Company may offer in the future. Moreover, these and other new products and services may be subject to significant competition with offerings by new and existing competitors in the business. In addition, new products and services may pose a variety of challenges and require the Company to attract additional qualified employees. The failure to successfully develop and market these new products and services could seriously harm the Company's business, financial condition and results of operations.

### ***Unfavourable publicity or consumer perception***

Management of the Company believes the recreational cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the recreational cannabis produced. Cannabis is a controversial topic, and consumer perception of the Company's proposed products may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of recreational cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the recreational cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company's proposed products and the business, results of operations, financial condition and cash flows. The Company's dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for the Company's proposed products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of recreational cannabis in general, or the Company's proposed products specifically, or associating the consumption of recreational cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers' failure to consume such products appropriately or as directed.

In addition to consumers, the parties with which the Company does business may perceive that they are exposed to reputational risk as a result of the Company's cannabis business activities. Failure to establish or maintain business relationships could have a material adverse effect on the Company.

### ***Strategic Alliances***

The Company may in the future enter into, strategic alliances with third parties that the Company believes will complement or augment its existing business. The Company's ability to complete strategic alliances is dependent upon, and may be limited by, the availability of suitable candidates and capital. In addition, strategic alliances could present unforeseen regulatory issues, integration obstacles or costs, may not enhance the Company's business, and may involve risks that could adversely affect the Company, including significant amounts of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such strategic alliances. Future strategic alliances could result in the incurrence of additional debt, costs and contingent liabilities, and there can be no assurance that future strategic alliances will achieve the expected benefits to the Company's business or that the Company will be able to consummate future strategic alliances on satisfactory terms, or at all. Any of the foregoing could have a material adverse effect on the Company's business, financial condition and results of operations.

### ***Risks inherent in an agricultural business***

The Company's business involves the growing of recreational cannabis, an agricultural product. Such business are subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Although all growing is expected to be completed indoors under climate controlled conditions, there can be no assurance that natural elements will not have a material adverse effect on any such future production.

### ***Energy costs***

The Company's cannabis cultivation and production operations consumes considerable energy, which makes it vulnerable to rising energy costs. Accordingly, rising or volatile energy costs may, in the future, adversely impact the business of the Company and its ability to operate profitably. The Company relies on power provided by PG&E.

### ***Reliance on key personnel***

The Company's success has depended and continues to depend upon its ability to attract and retain key management and consultants. The Company will attempt to enhance its management and technical expertise by continuing to recruit qualified individuals who possess desired skills and experience in certain targeted areas. The Company currently receives the benefit of consultants who provide services to the Company under certain consulting agreements. The termination these agreements or the inability to access key personnel could have a material adverse effect on the Company's business, results of operations, sales, cash flow or financial condition. The loss of any of the Company's senior management or key consultants and employees could materially adversely affect the Company's ability to execute the Company's business plan and strategy, and the Company may not be able to find adequate replacements on a timely basis, or at all. The Company does not maintain key person life insurance policies on any of the Company's employees.

### ***Reliance on a single jurisdiction***

To date, the Company's activities and resources have been primarily focused within the State of California. The Company expects to continue the focus on this state as it continues to review further expansion opportunities into other jurisdictions in the United States. Adverse changes or developments within California could have a material and adverse effect on the Company's ability to continue producing cannabis, its business, financial condition and prospects.

### ***Environmental laws and employee health and safety regulations***

The Company's operations are subject to environmental and safety laws and regulations concerning, among other things, emissions and discharges to water, air and land, the handling and disposal of hazardous and non-hazardous materials and wastes, and employee health and safety. The Company incurs ongoing costs and obligations related to compliance with environmental and employee health and safety matters. Failure to obtain an environmental compliance approval under applicable regulations or otherwise comply with environmental and safety laws and regulations may result in additional costs for corrective measures, penalties or in restrictions on the Company's manufacturing operations.

In addition, changes in environmental, employee health and safety or other laws, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations or give rise to material liabilities, which could have a material adverse effect on the Company's business, results of operations and financial condition.

### ***Unknown environmental risks***

There can be no assurance that the Company will not encounter hazardous conditions at the site of the real estate used to operate its businesses, such as asbestos or lead, in excess of expectations that may delay the development of its businesses. Upon encountering a hazardous condition, work at the facilities of the Company may be suspended. If the Company receives notice of a hazardous condition, it may be required to correct the condition prior to continuing construction or operations. The presence of other hazardous conditions will likely delay construction or operations and may require significant expenditure of the Company's resources to correct the condition. Such conditions could have a material impact on the investment returns of the Company.

### ***Security risks***

The business premises of the Company's operating locations are targets for theft. While the Company has implemented security measures at its operating locations and continues to monitor and improve its security measures, its cultivation and processing facilities could be subject to break-ins, robberies and other breaches in security. If there is a breach in security and the Company falls victim to a robbery or theft, the loss of cannabis plants, cannabis oils, cannabis flowers and cultivation and processing equipment could have a material adverse impact on the business, financial condition and results of operation of the Company.

As the Company's business may involve the movement and transfer of cash which is collected from its locations and deposited into financial institutions, there is a risk of theft or robbery during the transport of cash. The Company may engage a security firm to provide security in the transport and movement of large amounts of cash. While the Company has taken steps to prevent theft or robbery of cash during transport, there can be no assurance that there will not be a security breach during the transport and the movement of cash involving the theft of product or cash.

### ***Information technology risks***

The Company's operations depend, in part, on how well the Company and its suppliers protect networks, equipment, IT systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism and theft. The Company's operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, IT systems and software, as well as pre-emptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays and/or increase in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact The Company's reputation and results of operations.

The Company has not experienced any material losses to date relating to cyber-attacks or other information security breaches, but there can be no assurance that the Company will not incur such losses in the future. The Company's risk and exposure to these matters cannot be fully mitigated because of, among other things, the evolving nature of these threats. As a result, cyber security and the continued development and enhancement of controls, processes and practices designed to protect systems, computers, software, data and networks from attack, damage or unauthorized access is a priority. As cyber threats continue to evolve, the Company may be required to expend additional resources to continue to modify or enhance protective measures or to investigate and remediate any security vulnerabilities.

### ***Product recalls***

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of the Company's products are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Company may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although the Company has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits.

Additionally, if one of the Company's significant brands were subject to recall, the image of that brand and the Company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the Company's products and could have a material adverse effect on the results of operations and financial condition of the Company. Additionally, product recalls may lead to increased scrutiny of the Company's operations by the U.S. Food and Drug Administration, or other regulatory agencies, requiring further management attention and potential legal fees and other expenses. Furthermore, any product recall affecting the cannabis industry more broadly could lead consumers to lose confidence in the safety and security of the products sold by Cannabis license holders generally, which could have a material adverse effect on the Company's business, financial condition and results of operations.

### ***Results of future clinical research***

Research in Canada, the United States and internationally regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis or isolated cannabinoids (such as cannabidiol ("CBD") and tetrahydrocannabinol ("THC")) remains in early stages. There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC). Future research studies and clinical trials may draw opposing conclusions or reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to cannabis, which could have a material adverse effect on the demand for the Company's products with the potential to lead to a material adverse effect on the Company's business, financial condition, results of operations or prospects.

### ***Competition***

The Company will face intense competition from other companies, some of which have longer operating histories and more financial resources and manufacturing and marketing experience than the Company. Increased competition by larger and better financed competitors could materially and adversely affect the proposed business, financial condition and results of operations of the Company.

Because of the early stage of the industry in which the Company operates, the Company expects to face additional competition from new entrants. If the number of users of recreational cannabis in the states in which the Company will operate its business increases, the demand for products will increase and the Company expects that competition will become more intense, as current and future competitors begin to offer an increasing number of diversified products.

The Company's future success depends upon its ability to achieve competitive per unit costs through increased production and the Company's ability to recognize higher margins through the sale of higher margin products. To the extent that the Company is not able to produce its products at competitive prices or consumers prioritize established low margin products over innovative, higher margin products, the Company's business, financial conditions and operations could be materially and adversely affected.

To remain competitive, the Company will require a continued high level of investment in research and development, marketing, sales and client support. The Company may not have sufficient resources to maintain research and development, marketing, sales and client support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of its operations.

### ***Licenses***

The Company's cannabis licenses are subject to ongoing compliance and reporting requirements. Failure by the Company to comply with the requirements of licenses or any failure to maintain licenses would have a material adverse impact on the business, financial condition and operating results of the Company. Should the relevant Californian governing bodies not grant, extend or renew any license or should it renew such license on different terms, or should it decide to grant more than the anticipated number of licenses, the business, financial condition and results of the operation of the Company could be materially adversely affected.

### ***Future acquisitions or dispositions***

The Company's business strategy contemplates future acquisitions and expansion of the Company's business activities. Material acquisitions, dispositions and other strategic transactions involve a number of risks, including: (i) potential disruption of the Company's ongoing business; (ii) distraction of management; (iii) the Company may become more financially leveraged; (iv) the anticipated benefits and cost savings of those transactions may not be realized fully or at all or may take longer to realize than expected; (v) increasing the scope and complexity of the Company's operations; and (vi) loss or reduction of control over certain of the Company's assets. Additionally, the Company may issue additional Common Shares in connection with such transactions, which would dilute a shareholder's holdings in the Company.

The presence of one or more material liabilities of an acquired company that are unknown to the Company at the time of acquisition could have a material adverse effect on the business, results of operations, prospects and financial condition of the Company. A strategic transaction may result in a significant change in the nature of the Company's business, operations and strategy. In addition, the Company may encounter unforeseen obstacles or costs in implementing a strategic transaction or integrating any acquired business into the Company's operations.

### ***Insurance and uninsured risks***

The Company's business is subject to a number of risks and hazards generally, including adverse environmental conditions, accidents, labour disputes and changes in the regulatory environment. Such occurrences could result in damage to assets, personal injury or death, environmental damage, delays in operations, monetary losses and possible legal liability.

Although the Company intends to continue to maintain insurance to protect against certain risks in such amounts as it considers to be reasonable, its insurance will not cover all the potential risks associated with its operations. The Company may also be unable to maintain insurance to cover these risks at economically feasible premiums. Insurance coverage may not continue to be available or may not be adequate to cover any resulting liability. Moreover, insurance against risks such as environmental pollution or other hazards encountered in the operations of the Company is not generally available on acceptable terms. The Company might also become subject to liability for pollution or other hazards which may not be insured against or which the Company may elect not to insure against because of premium costs or other reasons. Losses from these events may cause the Company to incur significant costs that could have a material adverse effect upon its financial performance and results of operations.

### ***Dependence on key inputs, suppliers and skilled labour***

The cannabis business is dependent on a number of key inputs and their related costs including raw materials and supplies related to growing operations, as well as electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition, results of operations or prospects of the Company. Some of these inputs may only be available from a single supplier or a limited group of suppliers. If a sole source supplier was to go out of business, the Company might be unable to find a replacement for such source in a timely manner or at all. If a sole source supplier were to be acquired by a competitor, that competitor may elect not to sell to the Company in the future. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition, results of operations or prospects of the Company. The ability of the Company to compete and grow will be dependent on it having access, at a reasonable cost and in a timely manner, to skilled labour, equipment, parts and components. No assurances can be given that the Company will be successful in maintaining its required supply of skilled labour, equipment, parts and components. This could have an adverse effect on the financial results of the Company.

The Company is reliant on third-party suppliers to develop and manufacture its products. Due to the uncertain regulatory landscape for regulating cannabis in the United States, the Company's third party suppliers, manufacturers and contractors may elect, at any time, to decline or withdraw services necessary for the operations of the Company. Loss of these suppliers, manufacturers and contractors may have a material adverse effect on the business and operational results of the Company.

### ***Difficulty to forecast***

The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the recreational cannabis industry in the states in which the Company's business will operate. A failure in the demand for its products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company.

### ***Management of growth***

The Company may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Company to deal with this growth may have a material adverse effect on the Company's business, financial condition, results of operations and prospects.

### ***Internal controls***

Effective internal controls are necessary for the Company to provide reliable financial reports and to help prevent fraud. Although the Company has undertaken a number of procedures and implemented a number of safeguards, in each case, in order to help ensure the reliability of its financial reports, including those imposed on the Company under Canadian securities law, the Company cannot be certain that such measures will ensure that the Company will maintain adequate control over financial processes and reporting. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company's results of operations or cause it to fail to meet its reporting obligations.

If the Company or its auditors discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market's confidence in the Company's consolidated condensed interim financial statements and materially adversely affect the trading price of Common Shares.

### ***Failure to comply with anti-bribery laws***

The Company is subject to the Corruption of Foreign Public Officials Act (Canada) ("CFPOA") and the United States Foreign Corrupt Practices Act ("FCPA"), which generally prohibit companies and company employees from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. The CFPOA and the FCPA also require companies to maintain accurate books and records and internal controls, including at foreign controlled subsidiaries. In addition, the Company may become subject to other anti-bribery laws of any nations in which it conducts business that apply similar prohibitions as the CFPOA and FCPA (e.g. the Organization for Economic Co-operation and Development Anti-Bribery Convention). The Company's employees or other agents may, without the Company's knowledge and despite the Company's efforts, engage in prohibited conduct under the Company's policies and procedures and the CFPOA, the FCPA or other anti-bribery laws to which the Company may be subject for which the Company may be held responsible. If the Company's employees or other agents are found to have engaged in such practices, the Company could suffer severe penalties and other consequences that may have a material adverse effect on the Company's business, financial condition and results of operations.

### ***Conflict of interest***

Certain of the Company's directors and officers are also directors and officers of other companies. Situations may arise in connection with potential acquisitions or opportunities where the other interests of these directors and officers conflict with or diverge from the Company's interests. In accordance with the BCBCA, directors who have a material interest in any person who is a party to a material contract or a proposed material contract are required, subject to certain exceptions, to disclose that interest and generally abstain from voting on any resolution to approve the contract.

### ***Litigation***

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Monitoring and defending against legal actions, whether or not meritorious, can be time-consuming, divert management's attention and resources and cause the Company to incur significant expenses. In addition, legal fees and costs incurred in connection with such activities may be significant and the Company could, in the future, be subject to judgments or enter into settlements of claims for significant monetary damages. Substantial litigation costs, even if the Company wins, or an adverse result in any litigation may adversely affect the Company's ability to continue operating and the market price for Common Shares and could use significant resources.

### ***Product liability***

The Company faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury. In addition, the sale of the Company's products would involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of the Company's products alone or in combination with other medications or substances could occur. The Company may be subject to various product liability claims, including, among others, that the Company's products caused injury or illness or death, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against the Company could result in increased costs, could adversely affect the Company's reputation with its clients and consumers generally, and could have a material adverse effect on the business, results of operations and financial condition of the Company. There can be no assurances that the Company will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities.

Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Company's potential products.

### ***General economic and political risks***

The Company may be affected by possible political or economic instability. The risks include, but are not limited to, terrorism, military repression, extreme fluctuations in currency exchange rates, high rates of inflation or unemployment, consumer trends and spending. Changes in medicine and agricultural development or investment policies or shifts in political attitude in certain countries may adversely affect the Company's business. Operations may be affected in varying degrees by government regulations with respect to restrictions on production, distribution, price controls, export controls, income taxes, expropriation of property, maintenance of assets, environmental legislation, land use, land claims of local people and water use. The effect of these factors cannot be accurately predicted.

### ***The Company is a Canadian company and shareholder protections differ from shareholder protections in the United States and elsewhere***

The Company is organized and exists under the laws of British Columbia, Canada and, accordingly, is governed by the BCBCA. The BCBCA differs in certain material respects from laws generally applicable to United States corporations and shareholders, including the provisions relating to interested directors, mergers and similar arrangements, takeovers, shareholders' suits, indemnification of directors and inspection of corporation records.

### **Risks Related to Securities**

#### ***Volatile market price for the Company's securities***

The market price for the Securities may be volatile and subject to wide fluctuations in response to numerous factors, many of which will be beyond the Company's control, including, but not limited to the following: (i) actual or anticipated fluctuations in the Company's quarterly results of operations; (ii) recommendations by securities research analysts; (iii) changes in the economic performance or market valuations of companies in the industry in which the Company will operate; (iv) addition or departure of the Company's executive officers and other key personnel and consultants; (v) release or expiration of transfer restrictions on outstanding Securities; (vi) sales or perceived sales of additional shares; (vii) operating and financial performance that vary from the expectations of management, securities analysts and investors; (viii) regulatory changes affecting the Company's industry generally and its business and operations both domestically and abroad; (ix) announcements of developments and other material events by the Company or its competitors; (x) fluctuations in the costs of vital production materials and services; (xi) changes in global financial markets and global economies and general market conditions, such as interest rates and pharmaceutical product price volatility; (xii) significant acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by or involving the Company or its competitors; (xiii) operating and share price performance of other companies that investors deem comparable to the Company or from a lack of market comparable companies; and (xiv) news reports relating to trends, concerns, technological or competitive developments, regulatory changes and other related issues in the Company's industry or target markets. Such volatility may affect the price at which you could sell any of the securities of the Company, and the sale of substantial amounts of securities could adversely affect the price of Common Shares.

Financial markets have recently experienced significant price and volume fluctuations that have particularly affected the market prices of equity securities of companies and that have often been unrelated to the operating performance, underlying asset values or prospects of such companies. Accordingly, the market price of each of the Company's securities may decline even if the Company's operating results, underlying asset values or prospects have not changed. Additionally, these factors, as well as other related factors, may cause decreases in asset values that are deemed to be other than temporary, which may result in impairment losses. There can be no assurance that continuing fluctuations in price and volume will not occur. If such increased levels of volatility and market turmoil continue, the Company's operations could be adversely impacted, and the trading price of the Securities may be materially adversely affected.

***The Company may not pay dividends***

The Company has not paid dividends in the past and does not anticipate paying dividends in the near future. The Company expects to retain its earnings to finance further growth and, when appropriate, retire debt. Any decision to pay dividends on the Common Shares in the future will be at the discretion of the Company's board of directors and will depend on, among other things, the Company's results of operations, current and anticipated cash requirements and surplus, financial condition, any future contractual restrictions and financing agreement covenants, solvency tests imposed by corporate law and other factors that the board of directors may deem relevant. As a result, investors may not receive any return on an investment in the Common Shares unless they are able to sell their shares for a price greater than that which such investors paid for them.

***Future sales or issuances of securities could decrease the value of securities, dilute investors' voting power and reduce earnings per share***

The Company may sell additional securities in subsequent offerings (including through the sale of securities convertible into equity securities and may issue equity securities in acquisitions). The Company cannot predict the size of future issuances of equity securities or the size and terms of future issuances of debt instruments or other securities convertible into equity securities or the effect, if any, that future issuances and sales of debt instruments or securities will have on the market price of the securities, where there is a market for such securities.

Issuance by the Company or sales by the Company or its existing security holders or substantial numbers of securities, or the perception that such issuances or sales could occur, may adversely affect the prevailing market prices for securities and result in dilution, possibly substantial, to current security holders. Such issuances or sales could occur at prices less than the current market price for such securities. Exercises of presently outstanding share options or warrants may also result in dilution to security holders.

***The regulated nature of the Company's business may impede or discourage a takeover, which could reduce the market price of the Company's securities***

The Company requires and holds various government licenses to operate its business, which would not necessarily continue to apply to an acquirer of the Company's business following a change of control. These licensing requirements could impede a merger, amalgamation, takeover or other business combination involving the Company or discourage a potential acquirer from making a tender offer for Common Shares, which, under certain circumstances, could reduce the market price of the Company's securities.

***There is no assurance the Company will continue to meet the listing standards of the CSE or the OTCQX***

The Company must meet continuing minimum listing standards to maintain the listing of its Common Shares on the CSE and on the OTCQX (the "Listed Securities"). If the Company fails to comply with such listing standards and the CSE or the OTCQX delists any of the Listed Securities, the Company and its security holders could face significant material adverse consequences, including:

- a limited availability of market quotations for the delisted Listed Securities;
- reduced liquidity for such Listed Securities;
- a determination that such Listed Securities are "penny stock," which would require brokers trading in such Listed Securities to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for such Listed Securities;
- a limited amount of news about the Company and analyst coverage of it; and a decreased ability for the Company to issue additional securities or obtain additional equity or debt financing in the future.

The Company cannot assure that a market will exist or continue to develop or be sustained for its securities. If a market does not continue to develop or is not sustained, it may be difficult for investors to sell securities at an attractive price or at all. The Company cannot predict the prices at which its securities will trade.

### ***Currency fluctuations***

Due to the Company's present operations in the United States, its intention to continue future operations outside Canada, certain of its operating expenses being incurred in United States dollars and certain of its operating expenses being incurred in Canadian dollars, the Company is expected to be exposed to significant currency fluctuations. Recent events in the global financial markets have been coupled with increased volatility in the currency markets. All or substantially all of the Company's revenue will be earned in US dollars, but a portion of its operating expenses are incurred in Canadian dollars. The Company does not have currency hedging arrangements in place and there is no expectation that the Company will put any currency hedging arrangements in place in the future. Fluctuations in the exchange rate between the US dollar and the Canadian dollar may have a material adverse effect on the Company's business, financial position or results of operations.

### ***Additional information***

Additional information relating to the Company is available on SEDAR at [www.sedar.com](http://www.sedar.com) or at the Company's website ([www.nextgreenwave.com](http://www.nextgreenwave.com)), or at [info@nextgreenwave.com](mailto:info@nextgreenwave.com).

### **Shareholder Information**

Stock Exchange Listing – CSE : NGW / OTCQX: NXGWF

### **Registrar and Transfer Agent**

National Issuer Services Ltd.

### **Investor Contacts**

Phone: 1-604-609-6167

Email: [IR@nextgreenwave.com](mailto:IR@nextgreenwave.com)

(Paul Chow - Director)